

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11077031/publications.pdf>

Version: 2024-02-01

52  
papers

22,812  
citations

117571

34  
h-index

149623

56  
g-index

57  
all docs

57  
docs citations

57  
times ranked

18632  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. <i>New England Journal of Medicine</i> , 2005, 352, 1539-1549.	13.9	5,656
2	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	1.0	4,537
3	2021 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2022, 43, 561-632.	1.0	2,169
4	Impact of Formal Continuing Medical Education. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 867.	3.8	1,987
5	The perindopril in elderly people with chronic heart failure (PEP-CHF) study. <i>European Heart Journal</i> , 2006, 27, 2338-2345.	1.0	1,280
6	beta Blockade after myocardial infarction: systematic review and meta regression analysis. <i>BMJ: British Medical Journal</i> , 1999, 318, 1730-1737.	2.4	1,211
7	Understanding Patients' Adherence-Related Beliefs about Medicines Prescribed for Long-Term Conditions: A Meta-Analytic Review of the Necessity-Concerns Framework. <i>PLoS ONE</i> , 2013, 8, e80633.	1.1	799
8	Composite Outcomes in Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2554.	3.8	627
9	Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CARDiac RESynchronization-Heart Failure (CARE-HF) trial extension phase]. <i>European Heart Journal</i> , 2006, 27, 1928-1932.	1.0	586
10	Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. <i>British Journal of Psychiatry</i> , 2002, 180, 396-404.	1.7	510
11	2021 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 60, 727-800.	0.6	344
12	Continuing education meetings and workshops: effects on professional practice and health care outcomes. , 2001, , CD003030.		262
13	Effect of Cardiac Resynchronization on the Incidence of Atrial Fibrillation in Patients With Severe Heart Failure. <i>Circulation</i> , 2006, 114, 18-25.	1.6	225
14	Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a subanalysis of the CARE-HF trial. <i>European Journal of Heart Failure</i> , 2009, 11, 699-705.	2.9	202
15	Predicting the Long-Term Effects of Cardiac Resynchronization Therapy on Mortality From Baseline Variables and the Early Response. <i>Journal of the American College of Cardiology</i> , 2008, 52, 438-445.	1.2	186
16	Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. <i>European Journal of Heart Failure</i> , 2009, 11, 480-488.	2.9	167
17	2021 ESC/EACTS Guidelines for the management of valvular heart disease. <i>EuroIntervention</i> , 2022, 17, e1126-e1196.	1.4	161
18	The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. <i>European Heart Journal</i> , 2006, 28, 42-51.	1.0	159

#	ARTICLE	IF	CITATIONS
19	Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. <i>European Heart Journal</i> , 2007, 28, 1827-1834.	1.0	147
20	Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. <i>European Heart Journal</i> , 2007, 28, 1592-1597.	1.0	144
21	The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. <i>European Heart Journal</i> , 2008, 30, 782-788.	1.0	132
22	Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. <i>European Heart Journal</i> , 2005, 26, 2681-2688.	1.0	121
23	Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization Heart Failure (CARE-HF) trial. <i>European Journal of Heart Failure</i> , 2012, 14, 628-634.	2.9	121
24	Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.2	113
25	Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the Cardiac Resynchronisation-Heart Failure (CARE-HF) study. <i>American Heart Journal</i> , 2009, 157, 457-466.	1.2	96
26	Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge. <i>European Journal of Heart Failure</i> , 2007, 9, 491-501.	2.9	91
27	The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 172-185.	1.8	88
28	Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. <i>Health Technology Assessment</i> , 2016, 20, 1-176.	1.3	82
29	Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. <i>European Journal of Heart Failure</i> , 2012, 14, 487-494.	2.9	61
30	Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2009, 53, 608-611.	1.2	58
31	Composite and surrogate outcomes in randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2007, 334, 756-757.	2.4	51
32	How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?. <i>BMJ: British Medical Journal</i> , 2005, 331, 836-838.	2.4	43
33	The Limit of Plausibility for Predictors of Response: Application to Biventricular Pacing. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 1046-1065.	2.3	42
34	Weighing the pros and cons for composite outcomes in clinical trials. <i>Journal of Clinical Epidemiology</i> , 2007, 60, 658-659.	2.4	41
35	Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. <i>European Heart Journal</i> , 2009, 30, 2109-2116.	1.0	36
36	Predictors of Mortality From Pump Failure and Sudden Cardiac Death in Patients With Systolic Heart Failure and Left Ventricular Dyssynchrony: Results of the CARE-HF Trial. <i>Journal of Cardiac Failure</i> , 2008, 14, 670-675.	0.7	34

#	ARTICLE	IF	CITATIONS
37	Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty. <i>European Journal of Heart Failure</i> , 2007, 9, 92-97.	2.9	33
38	The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. <i>BMC Medical Research Methodology</i> , 2008, 8, 12.	1.4	33
39	On the pooling and subgrouping of data from percutaneous coronary intervention versus coronary artery bypass grafting trials: a call to circumspection. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 915-918.	0.6	17
40	Prevalence and inter-relationship of different Doppler measures of dyssynchrony in patients with heart failure and prolonged QRS: a report from CARE-HF. <i>Cardiovascular Ultrasound</i> , 2009, 7, 1.	0.5	12
41	Commentary: The left main controversy: Is this a real subgroup requiring custom clinical recommendations?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 108-110.	0.4	9
42	PROactive study. <i>Lancet</i> , The, 2006, 367, 24-25.	6.3	7
43	Beliefs of Health Care Providers, Lay Health Care Providers and Lay Persons in Nigeria Regarding Hypertension. A Systematic Mixed Studies Review. <i>PLoS ONE</i> , 2016, 11, e0154287.	1.1	7
44	Clinical trials update from the American College of Cardiology Meeting 2011: STICH, NorthStar, TARGET, and EVEREST II. <i>European Journal of Heart Failure</i> , 2011, 13, 805-808.	2.9	6
45	Transcatheter versus surgical aortic valve replacement: what does the latest evidence tell us?. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 7-9.	0.6	6
46	Physiotherapy trials for the 21st century – time to raise the bar?. <i>Journal of the Royal Society of Medicine</i> , 2011, 104, 437-441.	1.1	5
47	Can cardiac-resynchronization therapy reduce mortality in patients suffering from advanced chronic heart failure?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2004, 1, 10-11.	3.3	3
48	Composite outcomes – final comment for now. <i>Journal of Clinical Epidemiology</i> , 2007, 60, 662.	2.4	3
49	The conundrum of the treatment for left main coronary disease. <i>European Heart Journal</i> , 2020, 41, 3236-3238.	1.0	3
50	Answering important questions reliably-GISSI Heart Failure, a factorially designed trial with composite (co)primary outcome measures. <i>European Journal of Heart Failure</i> , 2004, 6, 531-533.	2.9	2
51	The review by Weinmann and colleagues. <i>Psychopharmacology</i> , 2008, 199, 131-132.	1.5	2
52	The path for medical associations to sponsor trustworthy guidelines: is it feasible?. <i>Journal of the Royal Society of Medicine</i> , 2022, 115, 252-256.	1.1	2